JB-11 isethionate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596196

CAS#: 82935-04-4

Description: JB-11 isethionate is a bioactive chemical.


Chemical Structure

img
JB-11 isethionate
CAS# 82935-04-4

Theoretical Analysis

MedKoo Cat#: 596196
Name: JB-11 isethionate
CAS#: 82935-04-4
Chemical Formula: C21H29N5O7S
Exact Mass:
Molecular Weight: 495.55
Elemental Analysis: C, 50.90; H, 5.90; N, 14.13; O, 22.60; S, 6.47

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: JB-11 isethionate; NSC 328564; NSC-328564; NSC328564;

IUPAC/Chemical Name: 5-methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)quinazoline-2,4-diamine 2-hydroxyethane-1-sulfonate

InChi Key: YATKEMOVGUXIDY-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H23N5O3.C2H6O4S/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3;3-1-2-7(4,5)6/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24);3H,1-2H2,(H,4,5,6)

SMILES Code: OCCS(=O)(O)=O.NC1=NC(N)=C2C(C)=C(CNC3=CC(OC)=C(OC)C(OC)=C3)C=CC2=N1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 495.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Smith D, Gazzard B. Treatment and prophylaxis of Pneumocystis carinii pneumonia in AIDS patients. Drugs. 1991 Oct;42(4):628-39. Review. PubMed PMID: 1723365.

2: Hughes WT. Prevention and treatment of Pneumocystis carinii pneumonia. Annu Rev Med. 1991;42:287-95. Review. PubMed PMID: 2035974.

3: Wordell CJ, Hauptman SP. Treatment of Pneumocystis carinii pneumonia in patients with AIDS. Clin Pharm. 1988 Jul;7(7):514-27. PubMed PMID: 3138063.

4: Masur H, Kovacs JA. Treatment and prophylaxis of Pneumocystis carinii pneumonia. Infect Dis Clin North Am. 1988 Jun;2(2):419-28. Review. PubMed PMID: 3060526.

5: Allegra CJ, Chabner BA, Tuazon CU, Ogata-Arakaki D, Baird B, Drake JC, Masur H. Treatment of Pneumocystis carinii pneumonia with trimetrexate in acquired immunodeficiency syndrome (AIDS). Semin Oncol. 1988 Apr;15(2 Suppl 2):46-9. PubMed PMID: 2966985.

6: Hughes WT. Treatment and prophylaxis for Pneumocystis carinii pneumonia. Parasitol Today. 1987 Nov;3(11):332-5. PubMed PMID: 15462879.

7: Allegra CJ, Chabner BA, Tuazon CU, Ogata-Arakaki D, Baird B, Drake JC, Simmons JT, Lack EE, Shelhamer JH, Balis F, et al. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1987 Oct 15;317(16):978-85. PubMed PMID: 2958710.

8: Queener SF, Bartlett MS, Jay MA, Durkin MM, Smith JW. Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection. Antimicrob Agents Chemother. 1987 Sep;31(9):1323-7. PubMed PMID: 2445281; PubMed Central PMCID: PMC174935.